Myriad Genetics, Inc.  

(Public, NASDAQ:MYGN)   Watch this stock  
Find more results for Louise Gardner�
37.83
-0.17 (-0.45%)
Real-time:   12:43PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 37.64 - 38.30
52 week 20.02 - 42.50
Open 37.84
Vol / Avg. 291,090.00/701,517.00
Mkt cap 2.74B
P/E 16.58
Div/yield     -
EPS 2.28
Shares 72.80M
Beta 0.99
Inst. own 145%
Dec 4, 2014
Myriad Genetics Inc Annual Shareholders Meeting - 11:00AM EST - Add to calendar
Nov 12, 2014
Myriad Genetics Inc at Credit Suisse Healthcare Conference - 3:00PM EST - Add to calendar
Nov 4, 2014
Q1 2015 Myriad Genetics Inc Earnings Call - 4:30PM EST - Add to calendar
Nov 4, 2014
Q1 2015 Myriad Genetics Inc Earnings Release - 4:00PM EST - Add to calendar
Sep 10, 2014
Myriad Genetics Inc at Morgan Stanley Healthcare Conference
Aug 12, 2014
Q4 2014 Myriad Genetics Inc Earnings Call - Webcast
Aug 12, 2014
Q4 2014 Myriad Genetics Earnings Release
Aug 7, 2014
Myriad Genetics Inc at Piper Jaffray Heartland Summit
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2014
Net profit margin 17.82% 22.64%
Operating margin 28.21% 35.27%
EBITD margin - 37.04%
Return on average assets 16.45% 21.65%
Return on average equity 18.72% 24.35%
Employees 1,649 -
CDP Score - -

Address

320 Wakara Way
SALT LAKE CITY, UT 84108
United States - Map
+1-801-5843600 (Phone)
+1-801-5843640 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

Officers and directors

John T. Henderson M.D. Independent Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Peter D. Meldrum President, Chief Executive Officer, Director
Age: 66
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Walter M. Gilbert Ph.D. Independent Vice Chairman of the Board
Bio & Compensation  - Reuters
T. Craig Benson President of Myriad RBM, Inc.
Age: 51
Bio & Compensation  - Reuters
Mark C. Capone President of Myriad Genetic Laboratories, Inc.
Age: 51
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Richard M. Marsh Esq. Executive Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Jayne B. Hart Executive Vice President - Human Resources
Age: 53
Bio & Compensation  - Reuters
Gary A. King Executive Vice President - International Operations
Age: 57
Bio & Compensation  - Reuters
Ronald S. Rogers Executive Vice President - Corporate Communications
Age: 45
Bio & Compensation  - Reuters
Robert Gardner Harrison Chief Information Officer
Age: 47
Bio & Compensation  - Reuters